Skip to content

Study of Biomorkers and Rehabilitation Strategies in Functional Motor Disorders (FMD)

A Window Into the Mind-brain-body Interplay: Development of Diagnostic, Prognostic Biomarkers and Rehabilitation Strategies in Functional Motor Disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06328790
Enrollment
450
Registered
2024-03-25
Start date
2023-05-31
Completion date
2025-05-31
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Motor Disorders

Keywords

Non motor symptoms, Motor symptoms, Exteroception, Interoception, Neurophysiological, MRI assessment, Diagnosis, Behavioral

Brief summary

Functional motor disorders (FMD) are prevalent and highly disabling conditions characterized by abnormal movements (functional weakness, tremor, dystonia) significantly altered by distractive manoeuvres and incongruent with movement disorders seen in specific neurological diseases. FMDs are still misunderstood, diagnosed with delay, and not adequately treated, leading to reduced independence and high healthcare costs. Symptoms are physiologically associated with voluntary movement (distractibility, resolution with placebo) but are reported as involuntary. How this happens is yet a matter of debate. Identifying diagnostic and prognostic disease-specific biomarkers is an unmet need. The investigators will investigate motor, exteroceptive and interoceptive domains in a large cohort of FMD patients by a comprehensive set of behavioural, neurophysiological, and MRI tests. Ad-hoc eXplainable Artificial Intelligence (XAI) methods will develop disease-specific diagnostic and prognostic biomarker algorithms.

Detailed description

Functional motor disorders (FMD) are part of the broad spectrum of functional neurological disorders characterized by abnormal movements (functional limb weakness, tremor, dystonia) significantly altered by distractive manoeuvres and incongruent with movement disorders seen in specific neurological diseases. FMDs have a high prevalence, are still misunderstood, diagnosed with a long delay, and not adequately treated, leading to high degrees of disability and poor quality of life with increasing social and economic costs. The old concept of psychological factors as the primary cause (conversion disorder) has been abandoned due to the lack of evidence about their causal role. According to a predictive coding account, the emerging idea is that symptoms and disability in FMD may depend on dysfunctions of a specific neural system integrating interoception, exteroception, and motor control. The idea underpins the investigator's proposal that FMD symptoms are perceptions of the state of the body. Besides the main pathophysiological features (abnormal attentional focus, beliefs/expectations, and sense of agency), the lived experience of symptoms and their resulting disability may depend on a specific neural system integrating motor, exteroceptive and interoceptive domains. Therefore, dysfunction within this system can cause and sustain motor and non-motor symptoms in FMD. Three-stage research will be conducted. A large cohort of patients with a definite diagnosis of FMD (n=150) and healthy controls (n=150) will be investigated by behavioural, neurophysiological, and MRI tests to collect biomarkers in the motor, exteroceptive and interoceptive domains. Computational modelling of the behavioural, neurophysiological, and MRI biomarkers will be developed through eXplainable Artificial Intelligence (XAI) methods through a data mining approach (machine learning) to implement a diagnostic algorithm biomarker (objective 1). A cohort of patients with organic motor disorders (n=75) will undergo the same behavioural, neurophysiological, and MRI tests belonging to the resulting biomarker-based diagnostic algorithm for validation (objective 2). Finally, the modulation of the resulting biomarker-based diagnostic algorithm after rehabilitation and the correlations of motor and non-motor symptoms (NMSs) with clinical improvement will be investigated in a sub-group of patients with FMD to explore the predictive value (objective 3). Our proposal consists of 6 work packages (WP), all integrated to deliver our stated objectives over the project's lifetime to achieve these objectives. Communication and dissemination activities will include the project's visual identity, public website, social media, videos, and press releases. Our proposal will inform the research and clinical community on disease-specific biomarkers for diagnosing and prognosis patients with FMD. The proposed approach has significant potential to disentangle some of the poorly understood features of these disorders, potentially providing a platform for more fundamental insights into brain functioning and the development of precision medicine approaches in their management. The proposed approach can also give the clinicians validated examinations to make a correct early diagnosis. This will improve the management of FMD with a positive impact on the patient's disability and the socio-economic costs of the illness.

Interventions

OTHERMultidisciplinary Rehabilitation Training

34 Patients will attend the in-person 5-day rehabilitation program (2 h/day) followed by a 12-weeks telemedicine program (1 h/week).

BEHAVIORALCross-sectional study on patients with FMD and patients with structural/organic diseases

Each subject will undergo behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and interoceptive domains.

BEHAVIORALCross-sectional study on patients with FMD and healthy controls (HC)

Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and

Sponsors

IRCCS Ospedale San Raffaele
CollaboratorOTHER
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona
CollaboratorOTHER
Michele Tinazzi, MD, PhD
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Experiments 1 and 3 Inclusion Criteria for Patients with FMD: * Age higher or equal to 18 years * Clinically definite diagnosis of FMD

Exclusion criteria

for Patients with FMD: * Mini-Mental State Examination score lower or equal to 24 * Physical impairment precluding signing the informed consent for participation * Certified other neurological and/or psychiatric comorbidities * Contraindications for 3T MRI Inclusion Criteria for Healthy Controls (HC) \- Age higher or equal to 18 years

Design outcomes

Primary

MeasureTime frameDescription
Schizotypal Personality Questionnaire (SPQ)Before the intensive 5-day rehabilitation protocol (T0)It is a scale for the assessment of schizotypal personality based on DSM-III-R criteria (Total score: 0-74; cut-off: \< 8 & \> 42).
Velocity of Cop displacement in the mediolateral directions (mm/s)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).An electronic monaxial stabilometric platform will be used to collect the velocity of Cop displacement in the mediolateral directions.
Autism spectrum Quotient (AQ)Before the intensive 5-day rehabilitation protocol (T0)It is a 50-item self-report measure used to assess traits of autism in adults and adolescents aged 16 years and over (Total score: 0-50; cut-off: \> 29).
Simplified Functional Movement Disorders Rating Scale (S-FMDRS) scoreBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Objective-rated validated scale to rate the duration and severity of functional motor symptoms (range: 0-54; higher = worse).
Multidimensional Fatigue Inventory Scale (MFI-20) scoreBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).It evaluates fatigue differentiating general, physical, reduced-activity, reduced-motivation, and mental fatigue (subscale range: 4-20; higher = worse).
Brief Pain Inventory (BPI) scoreBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).It evaluates pain intensity (range: 0-40; higher = worse) and interference (range: 0-70; higher = worse).
Beck Anxiety Inventory (BAI) scoreBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).It evaluates anxiety (range: 0-63; higher = worse).
Beck Depression Inventory (BDI-II) scoreBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).It evaluates depression (range: 0-63; higher = worse).
12-item Short-Form Health Survey (SF-12) scoreBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).The health-Related QoL will be evaluated by the Mental Health and Physical functioning of the 12-item Short-Form Health Survey (SF-12) (range: 0-100; higher = better).
Toronto Alexithymia Scale (TAS-20) scoreBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).It evaluates the level of alexithymia (range: 20-100; higher = worse).
Direct adn indirect index of Sensory Attenuation (SA)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Sensory attenuation (SA) will be used to collect data
Joint angle at the elbow vibrated and reproducedBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Tonic vibration reflex (TVR) will be used to collect data
N2/P2 amplitudeBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Laser evoked potentials (LEP) will be used to collect data
Objective/Subjective heart rate ratioBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Heartbeat Perception Task (HPT) will be used to collect data
Cortical thickness and gray matter volumesBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Brain 3 Tesla MRI will be used to collect data
Clinical Global Impression (CGI) scoreAfter 3 months of the intensive 5-day rehabilitation protocol (T1).Self-rated perception of change will be assessed with the 7-point Clinical Global Impression (CGI) scale with scores from 1 (very much improved) to 7 (very much worse).
Gait speed (cm/sec)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Gait analysis will be used to collect gait speed (cm/s).
Swing time (%)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Gait analysis will be used to collect swing time (%).
Stride time (s)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Gait analysis will be used to collect stride time (s).
Stride length (cm)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Gait analysis will be used to collect stride length (cm).
Sway area (mm2)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).An electronic monaxial stabilometric platform will be used to collect sway area (mm2).
Stance time (sec)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).An electronic monaxial stabilometric platform will be used to collect stance time (sec).
Total excursion path (mm)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).An electronic monaxial stabilometric platform will be used to collect total excursion path (mm): area of oscillations of the Center of Pressure (CoP), CoP perimeter length
Velocity of Cop displacement in the anteroposterior directions (mm/s)Before the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).An electronic monaxial stabilometric platform will be used to collect the velocity of Cop displacement in the anteroposterior directions.

Other

MeasureTime frameDescription
Number of patients who refuse the treatmentBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).Recruitment rate.
Number of drop-outBefore the intensive 5-day rehabilitation protocol (T0) and after 3 months of the intensive 5-day rehabilitation protocol (T1).The number of dropouts before the end of treatment will be collected.

Countries

Italy

Contacts

Primary ContactMichele Tinazzi, PhD
michele.tinazzi@univr.it3480172554
Backup ContactMarialuisa Gandolfi, PhD
marialuisa.gandolfi@univr.it3491656108

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 7, 2026